Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

Recruiting · NCT02421705 · Interventional (participants receive a specific treatment) · Lead sponsor: KU Leuven

Interventions studied

Sample collection

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

Age range

18 Years to 65 Years

Sex

All (male and female)

Healthy volunteers

Yes - healthy volunteers may be accepted

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

For group 1: IBS
Irritable Bowel Syndrome (IBS) (ROME III criteria)
No obvious organic explanation for the IBS symptoms
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)
diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
remission is confirmed by at least one sigmoidoscopy
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
nly for group 3a:
Rome III criteria for IBS
Group 4: Healthy controls No abdominal (pain) complaints.
Group 5: active Crohn's disease
\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)
diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
remission is confirmed by at least one sigmoidoscopy
Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

For all groups:
co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting
Abdominal chirurgy (except for an uncomplicated appendectomy)

2 locations listed.